Show simple item record

dc.contributor.authorMei, Ting
dc.contributor.authorLlera, Alberto
dc.contributor.authorFloris, Dorothea L
dc.contributor.authorForde, Natalie J
dc.contributor.authorTillmann, Julian
dc.contributor.authorDurston, Sarah
dc.contributor.authorMoessnang, Carolin
dc.contributor.authorBanaschewski, Tobias
dc.contributor.authorHolt, Rosemary J
dc.contributor.authorBaron-Cohen, Simon
dc.contributor.authorRausch, Annika
dc.contributor.authorLoth, Eva
dc.contributor.authorDell'Acqua, Flavio
dc.contributor.authorCharman, Tony
dc.contributor.authorMurphy, Declan GM
dc.contributor.authorEcker, Christine
dc.contributor.authorBeckmann, Christian F
dc.contributor.authorBuitelaar, Jan K
dc.contributor.authorEU-AIMS LEAP group
dc.date.accessioned2020-12-08T00:30:27Z
dc.date.available2020-12-08T00:30:27Z
dc.date.issued2020-10-30
dc.identifier.issn2040-2392
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/314830
dc.description.abstractBACKGROUND: Voxel-based morphometry (VBM) studies in autism spectrum disorder (autism) have yielded diverging results. This might partly be attributed to structural alterations being associating with the combined influence of several regions rather than with a single region. Further, these structural covariation differences may relate to continuous measures of autism rather than with categorical case-control contrasts. The current study aimed to identify structural covariation alterations in autism, and assessed canonical correlations between brain covariation patterns and core autism symptoms. METHODS: We studied 347 individuals with autism and 252 typically developing individuals, aged between 6 and 30 years, who have been deeply phenotyped in the Longitudinal European Autism Project. All participants' VBM maps were decomposed into spatially independent components using independent component analysis. A generalized linear model (GLM) was used to examine case-control differences. Next, canonical correlation analysis (CCA) was performed to separately explore the integrated effects between all the brain sources of gray matter variation and two sets of core autism symptoms. RESULTS: GLM analyses showed significant case-control differences for two independent components. The first component was primarily associated with decreased density of bilateral insula, inferior frontal gyrus, orbitofrontal cortex, and increased density of caudate nucleus in the autism group relative to typically developing individuals. The second component was related to decreased densities of the bilateral amygdala, hippocampus, and parahippocampal gyrus in the autism group relative to typically developing individuals. The CCA results showed significant correlations between components that involved variation of thalamus, putamen, precentral gyrus, frontal, parietal, and occipital lobes, and the cerebellum, and repetitive, rigid and stereotyped behaviors and abnormal sensory behaviors in autism individuals. LIMITATIONS: Only 55.9% of the participants with autism had complete questionnaire data on continuous parent-reported symptom measures. CONCLUSIONS: Covaried areas associated with autism diagnosis and/or symptoms are scattered across the whole brain and include the limbic system, basal ganglia, thalamus, cerebellum, precentral gyrus, and parts of the frontal, parietal, and occipital lobes. Some of these areas potentially subserve social-communicative behavior, whereas others may underpin sensory processing and integration, and motor behavior.
dc.format.mediumElectronic
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectEU-AIMS LEAP group
dc.subjectHumans
dc.subjectMagnetic Resonance Imaging
dc.subjectLongitudinal Studies
dc.subjectAutistic Disorder
dc.subjectAdolescent
dc.subjectEurope
dc.subjectFemale
dc.subjectMale
dc.subjectGray Matter
dc.titleGray matter covariations and core symptoms of autism: the EU-AIMS Longitudinal European Autism Project.
dc.typeArticle
prism.issueIdentifier1
prism.publicationDate2020
prism.publicationNameMol Autism
prism.startingPage86
prism.volume11
dc.identifier.doi10.17863/CAM.61936
dcterms.dateAccepted2020-10-05
rioxxterms.versionofrecord10.1186/s13229-020-00389-4
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2020-10-30
dc.contributor.orcidMei, Ting [0000-0003-3029-4460]
dc.identifier.eissn2040-2392
rioxxterms.typeJournal Article/Review
pubs.funder-project-idEuropean Commission (278948)
pubs.funder-project-idEuropean Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA) FP7 Innovative Medicines Initiative (IMI) (115300)
cam.issuedOnline2020-10-30


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International